| Target Molecule | Bivalirudin |
| Synonyms | Angiomax, Angiox, BG-8967, Bivalirudin TFA |
| CAS Number | 128270-60-0 (free base); TFA salt supplied per specification |
| Sequence (3-Letter) | H-D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH |
| Sequence (1-Letter) | fPRPGGGGNGDFEEIPEEYL |
| Molecular Formula | C₉₈H₁₃₈N₂₄O₃₃ (anhydrous free base) |
| Molecular Weight | 2180.29 (free base); 2294.34 (TFA salt) |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥95%, ≥98% via HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | TFA (standard form), Acetate, or custom salt options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) with Aspartimide Suppression |
| Modification Options | Asp-Gly motif optimization, stable isotope labeling (13C, 15N), beta-aspartyl impurity standards, D-phenylalanine incorporation |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | Comprehensive COA, HPLC, MS, and isomeric purity verification provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
Bivalirudin (CAS 128270-60-0) is a 20-amino-acid synthetic linear peptide functioning as a direct thrombin inhibitor, structured with an N-terminal D-phenylalanine and an aggregation-prone poly-glycine linker (fPRPGGGGNGDFEEIPEEYL). We target this sequence to supply high-purity reference materials and raw materials for anticoagulation and cardiovascular research.
The Bivalirudin sequence contains a vulnerable Asp-Gly dipeptide motif (positions 9-10) prone to aspartimide formation and alpha/beta-aspartyl rearrangement during base-catalyzed Fmoc deprotection. Our peptide synthesis platform utilizes sterically hindered aspartic acid protecting groups (such as Asp(OMpe)) and optimized mild deprotection cocktails to suppress aspartimide cyclization.
Yes. We provide specialized peptide modification services for direct thrombin inhibitors. Options include the intentional synthesis of beta-aspartyl isomers as critical impurity reference standards, site-specific stable isotope labeling (13C, 15N) for quantitative LC-MS/MS bioanalysis, and deletion sequence controls.
Our manufacturing infrastructure scales production from milligram-level analytical batches to multigram and kilogram commercial quantities. We optimize preparative HPLC purification and controlled counter-ion exchange (supplying TFA or acetate salt forms) to guarantee strict batch-to-batch consistency.
We operate as an integrated technical partner providing complete peptide CDMO solutions. Our team manages sequence optimization, aspartimide mitigation, impurity profiling, analytical method validation, and regulatory documentation to support complex drug development pipelines.
Bivalirudin (CAS 128270-60-0), historically known under the brand name Angiomax, is a synthetic 20-amino-acid linear peptide acting as a specific, reversible direct thrombin inhibitor. Defined by the sequence fPRPGGGGNGDFEEIPEEYL, it mimics hirudin and requires precise synthesis technology to mitigate sequence-specific degradation pathways. Synpeptide delivers comprehensive custom synthesis solutions for this target molecule, demonstrating advanced technical expertise in aspartimide suppression, long-chain linear SPPS, and CDMO manufacturing.
Constructing Bivalirudin presents distinct synthetic challenges, most notably the presence of the Asp9-Gly10 motif. During standard Fmoc-based SPPS, basic deprotection conditions strongly promote the cyclization of the aspartic acid side chain into an unwanted aspartimide intermediate, which subsequently opens into inactive alpha- and beta-aspartyl peptide mixtures. Our custom peptide synthesis platform resolves these hurdles using optimized Solid-Phase Peptide Synthesis (SPPS) protocols with sterically bulky protecting groups (e.g., Asp(OMpe)) and modified piperidine cleavage solutions. By suppressing aspartimide formation, we deliver raw materials with rigorous purity specifications (typically ≥95% or ≥98% via HPLC).
Because beta-aspartyl isomers often co-elute with the target peptide during standard chromatography, robust analytical validation is essential. Through our peptide modification services, we synthesize deliberate beta-aspartyl variants and deletion analogues to serve as vital reference standards for stability-indicating assays. We also incorporate stable isotopes (13C, 15N) for quantitative mass spectrometry bioanalysis.
Transitioning a complex 20-residue peptide prone to sequence-specific degradation from analytical scale to commercial volume demands robust downstream process engineering. We execute large-scale peptide synthesis for Bivalirudin utilizing tightly controlled reactor conditions and high-capacity preparative HPLC purification. Our facilities accommodate requirements from milligram research batches to kilogram commercial lots, ensuring uniform counter-ion exchange (delivering the required TFA or acetate salt form) across all production volumes.
We deliver comprehensive technical support as a fully integrated peptide CDMO. Our development specialists assist pharmaceutical partners with process optimization, stability testing, impurity identification, and analytical method validation. Every batch is released with complete analytical documentation—including COA, HPLC purity traces, and exact mass confirmation—ensuring regulatory alignment for downstream therapeutic programs.
